Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients
- PMID: 28433500
- DOI: 10.1016/j.schres.2017.03.040
Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients
Abstract
The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials.
Trial registration: ClinicalTrials.gov NCT00439634 NCT00505076 NCT00505765 NCT00641745 NCT00930150 NCT00968851 NCT01077700 NCT01095562 NCT01192867 NCT01192880 NCT01192906 NCT01568216 NCT01655680 NCT01678755 NCT02281773.
Keywords: Cognition; MATRICS Consensus Cognitive Battery; Schizophrenia.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31. Schizophr Res. 2011. PMID: 21075600 Clinical Trial.
-
An empirical evaluation of the MATRICS Consensus Cognitive Battery in bipolar disorder.Bipolar Disord. 2014 May;16(3):318-25. doi: 10.1111/bdi.12134. Epub 2013 Oct 9. Bipolar Disord. 2014. PMID: 24119238
-
Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.Schizophr Res. 2013 May;146(1-3):244-8. doi: 10.1016/j.schres.2013.02.026. Epub 2013 Mar 15. Schizophr Res. 2013. PMID: 23507359 Free PMC article.
-
[Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].Rev Neurol. 2012 Nov 1;55(9):549-55. Rev Neurol. 2012. PMID: 23111994 Review. Spanish.
-
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC).Bipolar Disord. 2010 Jun;12(4):351-63. doi: 10.1111/j.1399-5618.2010.00830.x. Bipolar Disord. 2010. PMID: 20636632 Review.
Cited by
-
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.Transl Psychiatry. 2022 Nov 21;12(1):491. doi: 10.1038/s41398-022-02254-9. Transl Psychiatry. 2022. PMID: 36414626 Free PMC article. Clinical Trial.
-
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia.Curr Top Behav Neurosci. 2023;63:407-436. doi: 10.1007/7854_2022_382. Curr Top Behav Neurosci. 2023. PMID: 35915386 Review.
-
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia.Front Psychiatry. 2019 Sep 6;10:648. doi: 10.3389/fpsyt.2019.00648. eCollection 2019. Front Psychiatry. 2019. PMID: 31551837 Free PMC article. Review.
-
Commentary.Schizophr Bull. 2025 Mar 14;51(2):278-282. doi: 10.1093/schbul/sbae191. Schizophr Bull. 2025. PMID: 39982833 Free PMC article. No abstract available.
-
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials.Schizophr Bull. 2025 Mar 14;51(2):262-273. doi: 10.1093/schbul/sbae151. Schizophr Bull. 2025. PMID: 39982834 Free PMC article. Review.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous